Camp4 Therapeutics Files Form 4 for Routine 9k Option Grant

Rhea-AI Filing Summary

Camp4 Therapeutics Corp. (CAMP) filed a Form 4 disclosing a routine equity compensation grant to director and 10% owner Amir Nashat. On 06/25/2025 Nashat received 9,000 non-qualified stock options with an exercise price of $1.56 per share. All options vest on the earlier of (i) the first anniversary of the grant or (ii) the company’s next annual shareholder meeting, provided Nashat continues to serve on the board through that date. The options carry a 10-year term expiring 06/24/2035 and were reported as direct beneficial ownership. No shares of common stock were bought or sold; the filing reflects only the grant of derivative securities. The size of the award is modest and does not materially change the company’s share count or insider ownership profile.

Insights

Senior Securities Analyst

TL;DR: Routine director option grant; immaterial dilution; neutral impact.

The 9,000-share option grant to director/10% holder Amir Nashat aligns board incentives with shareholder value but is too small to affect valuation or float. An exercise price of $1.56 implies minimal in-the-money value unless the stock trades above that level. Vesting within a year ensures near-term alignment, while the 10-year term is standard. No open-market buying or selling occurred, so the filing offers limited insight into insider sentiment. Overall, I view the disclosure as administratively necessary and not impactful for investment decisions.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Nashat Amir

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 9,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nashat Amir

(Last) (First) (Middle)

C/O POLARIS PARTNERS

ONE MARINA PARK DRIVE, 8TH FL.

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.56	06/25/2025		A		9,000		(1)	06/24/2035	Common Stock	9,000	$0	9,000	D

Explanation of Responses:

1. The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date.

Remarks:

	/s/ Josh Mandel-Brehm, as Attorney-in-Fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CAMP report on the latest Form 4?

CAMP reported a grant of 9,000 stock options to director Amir Nashat on 06/25/2025.

What is the exercise price and term of the CAMP stock options granted?

The options carry an exercise price of $1.56 and expire on 06/24/2035 (10-year term).

When will the newly granted CAMP options vest?

They vest in full on the earlier of the first anniversary of the grant or the next annual shareholder meeting, subject to continued board service.

Did the insider buy or sell any CAMP common shares?

No. The filing only discloses a derivative grant; no common stock purchases or sales occurred.

Does this Form 4 materially affect CAMP’s share count or insider ownership?

The 9,000-share option grant is immaterial to total shares outstanding and does not materially alter insider ownership percentages.